2-(2-(2-(2-(4-bromophenoxy)ethoxy)ethoxy)ethoxy)ethan-1-ol | 333382-87-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(2-(2-(2-(4-bromophenoxy)ethoxy)ethoxy)ethoxy)ethan-1-ol
• 英文别名: 2-[2-[2-[2-(4-Bromophenoxy)ethoxy]ethoxy]ethoxy]ethanol
• CAS: 333382-87-9
• 化学式: C₁₄H₂₁BrO₅
• 分子量: 349.222
• InChiKey: KZTUIETYPJDIHX-UHFFFAOYSA-N

物化性质

• 沸点：
  436.6±40.0 °C(Predicted)
• 密度：
  1.334±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  20
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  57.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(2-(2-(2-(4-bromophenoxy)ethoxy)ethoxy)ethoxy)ethan-1-ol 在 四溴化碳 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以69%的产率得到1-bromo-4-(2-(2-(2-(2-bromoethoxy)ethoxy)ethoxy)ethoxy)benzene
  参考文献：
  名称：

  [EN] POLYCYCLIC COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES
  [FR] COMPOSÉS POLYCYCLIQUES ET MÉTHODES POUR LA DÉGRADATION CIBLÉE DE POLYPEPTIDES DU FIBROSARCOME RAPIDEMENT ACCÉLÉRÉ

  摘要：

  本公开涉及双功能化合物ULM—L—PTM，其作为快速加速纤维肉瘤（RAF，如c-RAF、A-RAF和/或B-RAF；目标蛋白）的调节剂具有实用性。具体而言，本公开涉及含有一端结合到相应E3泛素连接酶的Von Hippel-Lindau、cereblon、凋亡抑制蛋白或鼠双分子同源物2配体的双功能化合物，另一端结合到目标蛋白RAF的部分，使得目标蛋白与泛素连接酶靠近，以实现目标蛋白的降解（和抑制）。本公开展示了与目标蛋白的降解/抑制相关的广泛药理活性范围。本公开的化合物和组合物用于治疗或预防由目标蛋白的聚集或积累，或目标蛋白的构成性激活导致的疾病或紊乱。

  公开号：

  WO2020051564A1
• 作为产物：
  描述：

  2-[2-(2-苯氧基乙氧基)乙氧基]-乙醇 在 氢氧化钾 、 溴 、 十六烷基三甲基溴化铵 、 三溴化磷 作用下， 以 吡啶 、 水 为溶剂， 反应 50.0h， 生成 2-(2-(2-(2-(4-bromophenoxy)ethoxy)ethoxy)ethoxy)ethan-1-ol
  参考文献：
  名称：

  Selective bromination of the aromatic ring in ω-phenylpolyoxaalkanes and alkanols in micelles

  摘要：

  DOI：

  10.1016/s0040-4020(01)85934-2

文献信息

• COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES
  申请人：Arvinas, Inc.

  公开号：US20180179183A1

  公开（公告）日：2018-06-28

  The present disclosure relates to bifunctional compounds, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A-RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为快速加速纤维肉瘤（RAF，如c-RAF、A-RAF和/或B-RAF；目标蛋白）的调节剂而发挥作用。具体而言，本公开涉及含有一端为Von Hippel-Lindau、cereblon、凋亡抑制蛋白或鼠双分子同源物2配体的双功能化合物，该配体与相应的E3泛素连接酶结合，并且另一端含有结合目标蛋白RAF的基团，使得目标蛋白与泛素连接酶靠近，以实现目标蛋白的降解（和抑制）。本公开展示了与目标蛋白的降解/抑制相关的广泛药理活性范围。本公开的化合物和组合物用于治疗或预防由目标蛋白的聚集或积累，或目标蛋白的构成性激活导致的疾病或紊乱。
• Liquid crystalline paracyclophanes and ansa compounds—series of polyether macrocycles incorporating diacetylene, phenyl, biphenyl, p-terphenyl and 2,5-diphenyl-1,3,4-thiadiazole rigid cores
  作者：Torsten Hegmann、Bernhard Neumann、Raik Wolf、Carsten Tschierske

  DOI：10.1039/b416091f

  日期：——

  Series of different macrocyclic liquid crystals consisting of two rod-like aromatic cores connected at both terminal ends by polyether chains have been synthesised by various macrocyclisation reactions (template assisted etherification, Yamaguchi macrolactonisation, Glaser-coupling reaction). The nature and length of the rigid core have a dominant impact on the liquid crystalline phases formed. A stepwise increase of the length of one of the rigid cores leads to significant mesophase stabilisation, to the induction of lamellar phases and, in general, to wider mesophase ranges. The same types of mesophases but at much reduced transition temperatures are observed when flexible methylene linkages are incorporated into the macrocycles. Parallel pre-organisation of the calamitic cores and micro-segregation of chemically distinct molecular parts are discussed as the main driving forces for the mesophase behaviour of these macrocyclic compounds. Additionally, chiral macrocyclic liquid crystals exhibiting SmC* phases, cholesteric phases and blue phases have been synthesised. In contrast to the cyclophanes, ansa-compounds incorporating only one aromatic core within the macrocycle show either a monotropic nematic phase only or no liquid crystalline behaviour at all. An architecture combining the cyclophane structure with an ansa-unit and a molecule with a non-parallel pre-organisation of rod-like mesogenic cores as well does not show LC phases. The lack of LC behaviour for these compounds might be due to the molecular architecture resulting in a steric disturbance of packing that, in this way, does not allow for segregation of rigid and flexible units into distinct sub-domains.

  由两个棒状芳香核通过聚醚链在两端连接而成的一系列不同的宏环液晶已通过各种宏环化反应合成（模板辅助醚化、山口巨环化反应、格拉泽偶联反应）。刚性核心的性质和长度对形成的液晶相具有显著影响。逐步增加其中一个刚性核心的长度会显著稳定中间相，诱导出层状相，并且总体上扩大了中间相的范围。当将柔性亚甲基链接体引入宏环时，观察到相同类型的中间相，但其相变温度明显降低。讨论了直链核心的平行预先组织和化学不同分子部分的微相分离作为这些宏环化合物中间相行为的主要驱动力。此外，还合成了表现出SmC*相、胆甾相和蓝相的手性宏环液晶。不同于环芳烃，仅在宏环内部包含一个芳香核心的安萨化合物仅显示出单调的向列相或根本没有液晶行为。结合环芳烃结构与安萨单位的架构以及不平行预先组织的棒状介导核心的分子也未显示出液晶相。这些化合物缺乏液晶行为可能是由于分子架构导致的堆积立体障碍，从而不允许刚性和柔性单位分离成不同的子域。
• Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
  申请人：Arvinas, Inc.

  公开号：US10723717B2

  公开（公告）日：2020-07-28

  The present disclosure relates to bifunctional compounds, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A-RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，它们可用作快速加速纤维肉瘤（RAF，如c-RAF、A-RAF和/或B-RAF；靶蛋白）的调节剂。特别是，本公开内容涉及双功能化合物，其一端含有与相应 E3 泛素连接酶结合的 Von Hippel-Lindau、cereblon、抑制细胞凋亡蛋白或小鼠双敏同源物 2 配体，另一端含有与靶蛋白 RAF 结合的分子，从而将靶蛋白置于泛素连接酶附近，以实现对靶蛋白的降解（和抑制）。本公开物具有与降解/抑制靶蛋白相关的广泛药理活性。本公开的化合物和组合物可以治疗或预防由于靶蛋白的聚集或积聚或靶蛋白的组成性激活而导致的疾病或失调。
• Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
  申请人：ARVINAS OPERATIONS, INC.

  公开号：US11173211B2

  公开（公告）日：2021-11-16

  The present disclosure relates to bifunctional compounds, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A-RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，它们可用作快速加速纤维肉瘤（RAF，如c-RAF、A-RAF和/或B-RAF；靶蛋白）的调节剂。特别是，本公开内容涉及双功能化合物，其一端含有与相应 E3 泛素连接酶结合的 Von Hippel-Lindau、cereblon、抑制细胞凋亡蛋白或小鼠双敏同源物 2 配体，另一端含有与靶蛋白 RAF 结合的分子，从而将靶蛋白置于泛素连接酶附近，以实现对靶蛋白的降解（和抑制）。本公开物具有与降解/抑制靶蛋白相关的广泛药理活性。本公开的化合物和组合物可以治疗或预防由于靶蛋白的聚集或积聚或靶蛋白的组成性激活而导致的疾病或失调。
• Synthesis of Pyridinocrownophanes Exhibiting High Ag+-Affinity
  作者：Jun Nishimura、Seiichi Inokuma、Koichi Kimura、Takashi Funaki

  DOI：10.3987/com-99-s(i)1

  日期：——